Alto Neuroscience has raised $120m that will fund pivotal trials of its recently acquired candidate for treatment-resistant depression.
Roche, Nvidia’s ‘AI Factory’; Industry looks to soften MFN impact; Structure’s oral GLP-1 data; and more
Welcome to another edition of Endpoints Weekly — and happy spring! The weather may not feel very spring-like here in NYC (outside that false start



